Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flibanserin Efficacy and Safety in Premenopausal European Women with HSDD
NCT00491829Phase 3Completed
- Sponsor
- Sprout Pharmaceuticals
- Start
- Jun 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of flibanserin in hypoactive sexual desire disorder (HSDD) (3 arms), sponsored by Sprout Pharmaceuticals. Primary endpoint: Frequency of Satisfying Sexual Events at 24 weeks. Started Jun 2007; status: completed.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00491829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491829.